Treatment of Rheumatoid arthritis

To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this approach is to discover subgroups of patients that are characterized by a good or poor treatment outcome. Dennis and colleagues have identified distinct pretreatment gene expression profiles in affected synovial tissue specimens and a tissue type-related systemic protein pattern which are associated with a positive or negative clinical outcome to monotherapy with adalumimab (anti-TNFα) and tocilizumab (anti-IL-6 receptor). These observations assign biological pathways associated with response outcome and provide evidence for the existence of systemic, easy-to-measure predictive biomarkers for clinical benefit of these biologics.

In rheumatoid arthritis (RA), therapies with biologics targeting the below are successfully used worldwide.

  • TNFα
  • IL-6 receptor
  • T-cell co-stimulation
  • B cells

Related Conference of Treatment of Rheumatoid arthritis

Treatment of Rheumatoid arthritis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in